<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02385318</url>
  </required_header>
  <id_info>
    <org_study_id>PRG-NY-14-019</org_study_id>
    <nct_id>NCT02385318</nct_id>
  </id_info>
  <brief_title>To Compare Safety and Efficacy of Perrigo's Drug Product Compared to an FDA Approved Drug Product in the Treatment of Actinic Keratosis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Padagis LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Padagis LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare safety and efficacy of Perrigo's drug product&#xD;
      compared to an FDA approved drug product in the treatment of actinic keratosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Complete Clearance (Absence) of Actinic Keratosis Lesions as Determined by Visual Inspection of the Investigator</measure>
    <time_frame>Day 57</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">519</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>Test Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ingenol Mebutate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ingenol Mebutate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo product</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ingenol Mebutate (Perrigo)</intervention_name>
    <arm_group_label>Test Product</arm_group_label>
    <other_name>Perrigo product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ingenol Mebutate (Reference)</intervention_name>
    <arm_group_label>Reference product</arm_group_label>
    <other_name>Reference Listed Drug Product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo gel</intervention_name>
    <arm_group_label>Placebo product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Provide written informed consent/assent&#xD;
&#xD;
          2. Healthy male or non-pregnant females, &gt;18 years old&#xD;
&#xD;
          3. Subjects must have clinical diagnosis of actinic keratosis&#xD;
&#xD;
          4. Subjects must be in general good health and free from any clinically significant&#xD;
             disease that might interfere with the study evaluations in the opinion of the&#xD;
             investigator&#xD;
&#xD;
          5. Subjects must be willing to refrain from using non-approved products on the targeted&#xD;
             treatment area during the study period.&#xD;
&#xD;
          6. Subjects should be willing to refrain from using any type of bandage or dressing on&#xD;
             the treatment area or apply the gel to open skin wounds, infections, or exfoliative&#xD;
             dermatitis.&#xD;
&#xD;
          7. Subjects must be willing and able to comply with the requirements of the study for the&#xD;
             duration of the study period.&#xD;
&#xD;
          8. Females of childbearing potential willing to use an acceptable form of birth control&#xD;
&#xD;
        Exclusion&#xD;
&#xD;
          1. Females who are pregnant, nursing, or planning a pregnancy within the study&#xD;
             participation period&#xD;
&#xD;
          2. Subjects who are immunocompromised or HIV positive or who have any immune-system&#xD;
             disorders including auto-immune disease&#xD;
&#xD;
          3. Subjects who have or had an active herpes infection within 14 days prior to the&#xD;
             baseline visit&#xD;
&#xD;
          4. Subjects who have any evidence of carcinoma or any other cancer on the face and scalp&#xD;
&#xD;
          5. Presence of an incompletely healed wound within the treatment area or within 5cm of&#xD;
             the treatment area&#xD;
&#xD;
          6. Presence of any skin condition in the treatment area that may be made worse by&#xD;
             treatment with the study medication&#xD;
&#xD;
          7. Subjects who have used a tanning salon, tanning booth, sunbathing or have excessive&#xD;
             prolonged exposure to the sun 7 days prior to Visit 1/Day 1 (baseline) or planned&#xD;
             throughout the study&#xD;
&#xD;
          8. Subjects who plan to use artificial tanners within 5cm of the selected treatment area&#xD;
             throughout the study&#xD;
&#xD;
          9. Use of NSAIDs within 7 days from Visit 1/Day 1 (Baseline) or initiation during the&#xD;
             trial.&#xD;
&#xD;
         10. Subjects who had select cosmetic or therapeutic procedures within 2cm of the selected&#xD;
             treatment area and within 14 days of Visit 1/Day 1 (baseline) or within 10cm of the&#xD;
             selected treatment area planned anytime during the study.&#xD;
&#xD;
         11. Subjects who have had or are scheduling elective surgery within 1 month before or&#xD;
             after the study period&#xD;
&#xD;
         12. Prior use within 30 days of Visit 1/ Day 1 (baseline) or planned use during the study&#xD;
             of immunomodulators, immunosuppressive therapies, interferon, interferon inducers,&#xD;
             systemic corticosteroids, and cytotoxic drugs&#xD;
&#xD;
         13. Subjects undergoing treatment or received treatment within 8 weeks of Visit 1/Day 1&#xD;
             (baseline) and within 2cm of the selected area or planned during anytime in the study&#xD;
             of: 5-FU, imiquimod, diclofenac, photodynamic therapy used in combination with&#xD;
             photosensitizing cream.&#xD;
&#xD;
         14. Subjects who used PUVA or UVB therapy on the face or scalp within 6 months prior to&#xD;
             Visit 1/Day 1 (baseline) or are planning to receive PUVA therapy, UVB therapy, or&#xD;
             nonprescription UV light sources anywhere on the body during the study.&#xD;
&#xD;
         15. Subjects who have taken systemic chemotherapy medications within the last 6 months&#xD;
             prior to Visit 1/Day 1 (baseline) or planned use anytime during the study.&#xD;
&#xD;
         16. Subjects who have undergone resurfacing procedures within the last 6 months prior to&#xD;
             Visit 1/Day 1 (baseline) or planned use anytime during the study.&#xD;
&#xD;
         17. Subjects who have been treated within 1 month or planning to receive treatment with&#xD;
             systemic retinoids, hyaluronic acid, other medicated actinic keratosis therapy, or&#xD;
             topical steroids anywhere on the head during the study.&#xD;
&#xD;
         18. Subject who have a history of hypersensitivity or allergy to any ingredient in the&#xD;
             drug product.&#xD;
&#xD;
         19. Use of medicated make-up in the treatment area or significant change in the use of&#xD;
             consumer products within 30 days of Visit 1/Day 1 (baseline) and planned use or change&#xD;
             throughout the study.&#xD;
&#xD;
         20. Start or change of dose of hormonal treatment within the past 3 months (90 days) or&#xD;
             planned start/change throughout the study.&#xD;
&#xD;
         21. Subject consumes excessive alcohol, abuses drugs, or has a condition that could&#xD;
             compromise the subject's ability to comply with study requirements&#xD;
&#xD;
         22. Participation in any clinical study involving an investigational product, agent, or&#xD;
             device in the 30 days prior to Visit 1/Day 1 (baseline) or throughout the study&#xD;
&#xD;
         23. Subjects who have been previously enrolled in this study&#xD;
&#xD;
         24. Employee of the research center or private practice&#xD;
&#xD;
         25. Subjects who in the opinion of the investigator are unlikely to be able to follow the&#xD;
             restrictions of the protocol and complete the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 30, 2015</study_first_submitted>
  <study_first_submitted_qc>March 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2015</study_first_posted>
  <results_first_submitted>January 4, 2021</results_first_submitted>
  <results_first_submitted_qc>January 4, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 22, 2021</results_first_posted>
  <disposition_first_submitted>June 27, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>June 27, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 29, 2016</disposition_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis, Actinic</mesh_term>
    <mesh_term>Keratosis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 15, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT02385318/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 15, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT02385318/SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Test Product</title>
          <description>Ingenol Mebutate gel (Perrigo)</description>
        </group>
        <group group_id="P2">
          <title>Reference Product</title>
          <description>Ingenol Mebutate gel (Reference)</description>
        </group>
        <group group_id="P3">
          <title>Placebo Product</title>
          <description>Placebo gel&#xD;
Placebo gel</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="204"/>
                <participants group_id="P2" count="210"/>
                <participants group_id="P3" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="203"/>
                <participants group_id="P3" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Test Product</title>
          <description>Ingenol Mebutate&#xD;
Ingenol Mebutate (Perrigo)</description>
        </group>
        <group group_id="B2">
          <title>Reference Product</title>
          <description>Ingenol Mebutate&#xD;
Ingenol Mebutate (Reference)</description>
        </group>
        <group group_id="B3">
          <title>Placebo Product</title>
          <description>Placebo gel&#xD;
Placebo gel</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="204"/>
            <count group_id="B2" value="210"/>
            <count group_id="B3" value="105"/>
            <count group_id="B4" value="519"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.6" spread="9.66"/>
                    <measurement group_id="B2" value="67.9" spread="9.91"/>
                    <measurement group_id="B3" value="68.4" spread="9.67"/>
                    <measurement group_id="B4" value="67.9" spread="9.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="115"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                    <measurement group_id="B2" value="156"/>
                    <measurement group_id="B3" value="87"/>
                    <measurement group_id="B4" value="404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="198"/>
                    <measurement group_id="B2" value="208"/>
                    <measurement group_id="B3" value="100"/>
                    <measurement group_id="B4" value="506"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="203"/>
                    <measurement group_id="B2" value="207"/>
                    <measurement group_id="B3" value="104"/>
                    <measurement group_id="B4" value="514"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Complete Clearance (Absence) of Actinic Keratosis Lesions as Determined by Visual Inspection of the Investigator</title>
        <time_frame>Day 57</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Test Product</title>
            <description>Ingenol Mebutate&#xD;
Ingenol Mebutate (Perrigo)</description>
          </group>
          <group group_id="O2">
            <title>Reference Product</title>
            <description>Ingenol Mebutate&#xD;
Ingenol Mebutate (Reference)</description>
          </group>
          <group group_id="O3">
            <title>Placebo Product</title>
            <description>Placebo gel&#xD;
Placebo gel</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complete Clearance (Absence) of Actinic Keratosis Lesions as Determined by Visual Inspection of the Investigator</title>
          <population>Per protocol population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="176"/>
                <count group_id="O3" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>85% power of success</non_inferiority_desc>
            <param_type>Equivalence ratio</param_type>
            <param_value>1.11</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.38</ci_lower_limit>
            <ci_upper_limit>14.44</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>57 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Test Product</title>
          <description>Ingenol Mebutate&#xD;
Ingenol Mebutate (Perrigo)</description>
        </group>
        <group group_id="E2">
          <title>Reference Product</title>
          <description>Ingenol Mebutate&#xD;
Ingenol Mebutate (Reference)</description>
        </group>
        <group group_id="E3">
          <title>Placebo Product</title>
          <description>Placebo gel&#xD;
Placebo gel</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden Death, Probable Myocardial Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Acute Gastroenteritis/Food Poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Acute Sigmoid Diverticulitis/Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening of Right Hip Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Left Breast Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>APPLICATION SITE PAIN</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="204"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>APPLICATION SITE Pruritus</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="204"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jonathan Schwartz</name_or_title>
      <organization>Perrigo</organization>
      <phone>718-960-9900</phone>
      <email>jonathan.schwartz@perrigo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

